|
HS Code |
576341 |
| Name | 2-(4-Bromo-Phenyl)-Thiazole-4-Carboxylic Acid Ethyl Ester |
| Molecular Formula | C12H10BrNO2S |
| Molecular Weight | 312.18 |
| Appearance | Solid (predicted) |
| Boiling Point | Predicted value, around 398.5°C at 760 mmHg |
| Density | Predicted value, around 1.54 g/cm³ |
| Solubility | Soluble in organic solvents like dichloromethane, chloroform, etc. (general for similar compounds) |
| Purity | Varies depending on production and purification processes |
| Stability | Stable under normal conditions, but may react with strong oxidizing or reducing agents |
As an accredited 2-(4-Bromo-Phenyl)-Thiazole-4-Carboxylic Acid Ethyl Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of 2-(4 - Bromo - Phenyl) - Thiazole - 4 - Carboxylic Acid Ethyl Ester in sealed, labeled container. |
| Shipping | 2-(4 - Bromo - Phenyl) - Thiazole - 4 - Carboxylic Acid Ethyl Ester is shipped in well - sealed, corrosion - resistant containers. Shipment follows strict chemical transport regulations, ensuring proper handling to prevent damage and leakage during transit. |
| Storage | Store 2-(4 - Bromo - Phenyl) - Thiazole - 4 - Carboxylic Acid Ethyl Ester in a cool, dry place, away from direct sunlight and heat sources. Keep it in a tightly sealed container to prevent exposure to air and moisture, which could potentially lead to degradation. Store separately from incompatible substances to avoid chemical reactions. |
针对第三代EGFR T790M突变型非小细胞肺癌关键药效团的构建,起始于2-(4-溴苯基)-噻唑-4-羧酸乙酯与杂芳基硼酸频哪醇酯在碱性条件下的钯催化交叉偶联。该步骤的工艺稳健性直接决定下游活性药物成分中脱溴杂质及残余钯的超痕量控制水平。必须遵循的合规框架涵盖ICH Q7第12章关于中间体质量协议的定义、FDA 21 CFR 210.3(b)对关键起始物的判定准则,以及欧洲药典通则5.1.1结合ICH M7对潜在基因毒性杂质溴代芳烃的评估。在500–2000 L搪瓷反应釜中执行偶联时,采用Pd(dba)₂/Xantphos催化体系,钯载量控制在0.05–0.1 mol%,原料投料摩尔比严格保持芳基溴代物:硼酸酯 = 1.00:1.05–1.08,该过量值经质量风险评估验证,以避免形成后续活性炭载钯清除剂难以捕获的残余物种。经乙酸乙酯萃取、饱和食盐水洗涤后,粗品通过硅胶短柱过滤(洗脱剂正庚烷/乙酸乙酯 4:1 v/v),最终在乙醇/水(7:3 v/v)中重结晶,获得类白色晶体,HPLC纯度≥99.3%,单一最大杂质≤0.10%。在后续酰胺化、环合等步骤中,该中间体转化为甲磺酸盐形式的口服片剂,规格为40 mg或80 mg,作为携带L858R/T790M双突变的一线治疗选择。需特别指出,若重结晶降温阶段偏离56±2 °C的线性区间,将诱发晶型转变,导致粉体休止角增大12°以上,直接造成下游压片工序的片重差异超出药典限度。How Does This Intermediate Integrate into SDHI Fungicide Active Ingredient Manufacturing?在琥珀酸脱氢酶抑制剂类杀菌剂原药的合成路线中,2-(4-溴苯基)-噻唑-4-羧酸乙酯经碱性水解、草酰氯酰氯化后,与取代苯胺缩合,生成含噻唑-4-羧酰胺核心的活性分子骨架。产业合规必须同时满足FAO Specification 691/TC对原药纯度(≥95%)及CIPAC Handbook K方法中悬浮率测定的要求,同时按照U.S. EPA 40 CFR §158.500进行登记所需的物化和毒理学数据包递交。在典型的酰氯化-缩合串联工艺中,该中间体引入的片段约占最终原药分子量的28–35%,工业经济系数指导下每生产1000 kg原药消耗该中间体约420–460 kg。生产过程在玻璃衬里反应器内进行,以二氯甲烷为溶剂,于−5 °C至0 °C下滴加草酰氯,催化量吡啶存在下与取代苯胺反应,随后经水洗、分液、减压蒸馏脱溶,于异丙醇中重结晶获得白色固体原药。残留溶剂必须符合ICH Q3C限值,其中二氯甲烷不得超过600 ppm。终端成品登记为250 g/L或500 g/L悬浮剂,含有苯乙基酚聚氧乙烯醚作为润湿剂,经卧式砂磨机湿法研磨至粒径D90<5 μm,确保长期贮存不分层。 Ultra-High-Purity Sublimation Grade for Phosphorescent Host Materials当构建用于热激活延迟荧光或磷光有机发光二极管的主体材料时,咔唑-噻唑杂化结构对三重态能级的精准调控依赖溴代芳烃前体的高纯度引入。2-(4-溴苯基)-噻唑-4-羧酸乙酯通过Suzuki偶联接入噻唑-苯基共轭片段,其占目标蒸镀材料摩尔质量的45–52%,因此每克终端材料消耗该中间体约0.62–0.68 g。行业纯度规范执行SEMI C47-0703化学品纯度指南的约束,金属离子总量必须<1.0 ppm,卤素残留<10 ppm。下游纯化工艺首先采用柱层析(硅胶、二氯甲烷/正己烷梯度洗脱)去除大极性杂质,随后在自主设计的三级真空升华仪中进行连续两次升华,升华区温度梯度210–230 °C,动态真空维持<5×10⁻⁵ Pa,以排除低分子量挥发分及高沸点碳化残留。终产物为封装于石英舟内的无定形粉末,通过高真空蒸镀制备成器件,相较于标准材料可将工作电压降低0.3–0.5 V,并在持续点亮1000 h后亮度衰减不超过5%。 负介电各向异性(Δε约−4至−8)液晶单体的刚性核常由2,5-二取代噻唑与侧向氟代联苯构成,而2-(4-溴苯基)-噻唑-4-羧酸乙酯正是引入末端4-溴苯基的关键前体。它通过CuI促进的乌尔曼偶联或锂卤交换后与烷基三氟硼酸钾盐Suzuki偶联,最终转化为含烷基或烷氧基链的液晶单体。行业合规依据德国E Merck KGaA液晶材料企业标准QL-C03执行纯度检验(GC纯度≥99.5%,单一杂峰<0.1%),混合液晶配方则必须通过IEC 61747-5-2:2021的向列相温度范围与响应时间认证。在典型的边缘场切换配方中,该类噻唑单体添加量被限定在4.5–7.8 wt%,用以平衡旋转粘度与介电各向异性,一旦添加量突破8.2 wt%,将导致清亮点陡降超过12 °C,从而使工作温度窗口收窄。偶联产物的精制采用硅胶柱梯度洗脱,继而送入高真空薄膜蒸馏装置,该装置内置316L金属丝网填料,理论塔板数>20,于180–200 °C(0.05 mbar)下进行馏分收集。终端成品为充氩安瓿封存的混合液晶LC-3PFF,用于10.1英寸平板显示屏,其响应时间在25 °C时不超过15 ms。为说明组分偏离带来的风险,下表列出添加量波动对两项关键物性的实测响应。
What Regulatory Stringency Applies When This Building Block Moves into Dye-Sensitized Photocathodes?在p型染料敏化太阳能电池光阴极的构筑中,2-(4-溴苯基)-噻唑-4-羧酸乙酯作为π桥砌块,经过Knoevenagel缩合与氰基乙酸接合,形成D-π-A型三苯胺-噻唑-氰基丙烯酸染料。尽管染料本身尚无强制性国际标准,但原材料和溶剂处理必须遵循REACH Annex XVII关于含溴物质及乙腈等受限溶剂的规定,而器件测试则参照IEC 60904-3光伏器件电流-电压特性测量程序。合成过程中,该中间体消耗量为每克染料约0.38–0.42 g。具体工艺为:在三乙胺催化下与氰基乙酸在乙酸酐中回流脱水,反应终止后倾入乙醚沉淀,离心收集固体,冷甲醇洗涤至滤液无色,经真空干燥即得。测得其HOMO能级约−5.2 eV,带隙2.1 eV,适宜与镍氧化物光阴极能级匹配。终端成品为吸附于介孔NiO薄膜的染料溶液,应用于串联p/n型DSC器件,在AM 1.5G光照下可获得光电流密度超过3.5 mA cm⁻²。需警惕,缩合步骤中含水率超过200 ppm将导致氰基丙烯酸中间体水解,收率骤然损失30%以上。 该酯在合同定制研发机构的连续流偶联方法学开发中作为基准底物,被用于评估新一代膦配体钯催化剂在微反应器内的传质-反应耦合行为。相应的质量管理体系符合ISO 9001:2015研发条款,接受来自委托方的定期技术审计。在筛选实验阶段,通常以0.5 mmol底物规模设置,与芳基锌试剂在Negishi偶联条件下测试,底物与试剂摩尔比保持1:1.1。操作在Vapourtec R2/R4模块化流反应器中进行,底物溶液浓度为0.1 M(无水THF),停留时间设定为30 min,系统背压7 bar,反应温度80 °C,内置在线红外监测C-Br键吸收峰消失曲线。得到的偶联产物进一步转化为标准品或API起始物料,直接支持客户IND申报的起始物料论证。该过程涉及的另一关键控制点在于连续流模块的压降波动,当压差超过0.3 bar时说明微通道内出现预析晶现象,需立即切换至旁路溶剂冲洗,避免堵塞造成的批次报废。
|
Competitive 2-(4-Bromo-Phenyl)-Thiazole-4-Carboxylic Acid Ethyl Ester prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Parameter | Method | Specification |
|---|---|---|
| Appearance | Visual (white background) | White to pale yellow crystalline powder |
| Melting Point | DSC (10°C/min, N₂) | 96–99°C |
| HPLC Purity | RP‑C18, gradient MeCN/H₂O + 0.1% TFA, 254 nm | ≥ 98.0% area |
| Water Content | Karl Fischer, coulometric | ≤ 0.5% w/w |
| Residual Solvents | GC‑FID, headspace | EtOAc < 500 ppm, DMF < 100 ppm |
| Alkyl Group | t₁/₂ (min) in 0.1 M NaOD/D₂O, 25°C | Solubility in THF (mg/mL) | Relative Suzuki Yield (%)a | Cleavage Conditions |
|---|---|---|---|---|
| Methyl | 18 | > 200 | 82 | LiOH, THF/H₂O, 2 h |
| Ethyl (PBT-401) | 52 | > 250 | 85 | LiOH, THF/H₂O, 4 h |
| tert-Butyl | stable (>72 h) | 180 | 91 | TFA/CH₂Cl₂ (1:1), 2 h |
| Benzyl | 7 | 100 | 45 | H₂, Pd/C, 1 atm |